Table 1 Demographics and baseline disease characteristics for the Subset of PSA-matched African American and Caucasian patients with mCRPC who were treated with sipuleucel-T in PROCEED.
Sipuleucel-T-treated, PSA-matched patients | ||
|---|---|---|
African American patients (n = 219) | Caucasian patients (n = 438) | |
Median (min–max) age, years | 71 (42–94) | 72 (48–93) |
ECOG PS, n (%) | ||
0 | 138 (63) | 299 (68) |
1 | 76 (35) | 124 (28) |
2 | 3 (1) | 14 (3) |
3 | 1 (0.5) | 1 (0.2) |
Missing | 1 (0.5) | 0 |
Worst Gleason score sum, n (%) | ||
≤6 | 28 (13) | 61 (14) |
7 | 65 (30) | 135 (31) |
≥8 | 101 (46) | 212 (48) |
Missing | 25 (11) | 30 (7) |
Median (Q1–Q3) body weight, kg | 88 (79–102) | 90 (79–101) |
Median (Q1–Q3) PSA, ng/mL | 32.9 (8.6–89.7) | 28.7 (7.8–82.3) |
n | 219 | 438 |
Median (Q1–Q3) LDH, U/L | 191 (170–233) | 188 (157–220) |
n | 69 | 165 |
Median (Q1–Q3) ALP, U/L | 88 (69–115) | 83 (64–116) |
n | 170 | 361 |
Median (Q1–Q3) hemoglobin, g/dL | 12.1 (11.0–12.9) | 12.9 (11.9–13.7) |
n | 210 | 417 |
Median (Q1–Q3) time from diagnosis/biopsy to first infusion, years | 5.8 (2.5–10.8) | 4.9 (2.5–9.7) |
n | 169 | 395 |
Localization of disease, n (%) | ||
Bone only | 137 (63) | 270 (62) |
Bone and lymph nodes | 37 (17) | 85 (19) |
Bone and visceral | 5 (2) | 8 (2) |
Bone, lymph node and visceral | 4 (2) | 7 (2) |
Lymph node only | 31 (14) | 57 (13) |
Lymph node and visceral | 2 (1) | 1 (0.2) |
Visceral | 2 (1) | 6 (1) |
Missing | 1 (0.5) | 4 (1) |
Number of bone metastases, n (%) | ||
n | 183 | 370 |
≤10 | 129 (71) | 277 (75) |
>10 | 27 (15) | 76 (21) |
Missing | 26 (14) | 17 (5) |
Prior treatment, n (%) | ||
Primary radiation therapy | 99 (45) | 213 (49) |
Radical prostatectomy | 69 (32) | 148 (34) |
Chemotherapy | 25 (11) | 97 (22) |
